|
1
|
Sirica AE, Gores GJ, Groopman JD, Selaru
FM, Strazzabosco M, Wei Wang X and Zhu AX: Intrahepatic
cholangiocarcinoma: Continuing challenges and translational
advances. Hepatology. 69:1803–1815. 2019. View Article : Google Scholar :
|
|
2
|
Squires MH, Cloyd JM, Dillhoff M, Schmidt
C and Pawlik TM: Challenges of surgical management of intrahepatic
cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 12:671–681.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mavros MN, Economopoulos KP, Alexiou VG
and Pawlik TM: Treatment and prognosis for patients with
intrahepatic cholangiocarcinoma: Systematic review and
meta-analysis. JAMA Surg. 149:565–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farges O, Fuks D, Boleslawski E, Le Treut
YP, Castaing D, Laurent A, Ducerf C, Rivoire M, Bachellier P,
Chiche L, et al: Influence of surgical margins on outcome in
patients with intrahepatic cholangiocarcinoma: A multicenter study
by the AFC-IHCC-2009 study group. Ann Surg. 254:824–830. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Jong MC, Nathan H, Sotiropoulos GC,
Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM,
Aldrighetti L, et al: Intrahepatic cholangiocarcinoma: An
international multi-institutional analysis of prognostic factors
and lymph node assessment. J Clin Oncol. 29:3140–3145. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moeini A, Sia D, Bardeesy N, Mazzaferro V
and Llovet JM: Molecular pathogenesis and targeted therapies for
intrahepatic cholangiocarcinoma. Clin Cancer Res. 22:291–300. 2016.
View Article : Google Scholar
|
|
8
|
Gutschner T and Diederichs S: The
hallmarks of cancer: A long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ulitsky I and Bartel DP: LincRNAs:
Genomics, evolution, and mechanisms. Cell. 154:26–46. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang Y, Cheung BB, Atmadibrata B, Marshall
GM, Dinger ME, Liu PY and Liu T: The regulatory role of long
noncoding RNAs in cancer. Cancer Lett. 391:12–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gutschner T, Hammerle M and Diederichs S:
MALAT1-a paradigm for long noncoding RNA function in cancer. J Mol
Med (Berl). 91:791–801. 2013. View Article : Google Scholar
|
|
12
|
Zou Y, Zhong Y, Wu J, Xiao H, Zhang X,
Liao X, Li J, Mao X, Liu Y and Zhang F: Long non-coding PANDAR as a
novel biomarker in human cancer: A systematic review. Cell Prolif.
51:e124222018. View Article : Google Scholar
|
|
13
|
Chen JS, Wang YF, Zhang XQ, Lv JM, Li Y,
Liu XX and Xu TP: H19 serves as a diagnostic biomarker and
up-regulation of H19 expression contributes to poor prognosis in
patients with gastric cancer. Neoplasma. 63:223–230. 2016.
|
|
14
|
Zhang L, Yang Z, Trottier J, Barbier O and
Wang L: Long noncoding RNA MEG3 induces cholestatic liver injury by
interaction with PTBP1 to facilitate shp mRNA decay. Hepatology.
65:604–615. 2017. View Article : Google Scholar
|
|
15
|
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z,
Deng X, Chen H, Shen B, Peng C, et al: Upregulation of long
noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor
prognosis in hepatocellular carcinoma. Oncogene. 35:1575–1584.
2016. View Article : Google Scholar
|
|
16
|
Lv QL, Hu L, Chen SH, Sun B, Fu ML, Qin
CZ, Qu Q, Wang GH, He CJ and Zhou HH: A long noncoding RNA ZEB1-AS1
promotes tumorigenesis and predicts poor prognosis in glioma. Int J
Mol Sci. 17:pii: E1431. 2016. View Article : Google Scholar
|
|
17
|
Fu J and Cui Y: Long noncoding RNA
ZEB1-AS1 expression predicts progression and poor prognosis of
colorectal cancer. Int J Biol Markers. 32:e428–e433. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Wen X, Wang L, Sun X, Ma H, Fu Z and
Li L: LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric
cancer. Surg Oncol. 26:527–534. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Su W, Xu M, Chen X, Chen N, Gong J, Nie L,
Li L, Li X, Zhang M and Zhou Q: Long noncoding RNA ZEB1-AS1
epigenetically regulates the expressions of ZEB1 and downstream
molecules in prostate cancer. Mol Cancer. 16:1422017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng R, Li N, Yang S, Liu L and Han S:
Long non-coding RNA ZEB1-AS1 promotes cell invasion and epithelial
to mesenchymal transition through inducing ZEB1 expression in
cervical cancer. Onco Targets Ther. 11:7245–7253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ni Y, Fang J, Zhu L, Jiang H, Liu Y, Miao
R, Shao C and Shao S: The significant prognostic value of ZEB1-AS1
up-regulation in patients with cancer. J Cancer. 9:2502–2509. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Y, Ding M, Wei S, Wu T, Xu R, Zhu X and
Liu H: The prognostic value of long noncoding RNA ZEB1-AS1 on
clinical outcomes in human cancer. J Cancer. 9:3690–3698. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar
|
|
24
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.
View Article : Google Scholar
|
|
25
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop-a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hill L, Browne G and Tulchinsky E:
ZEB/miR-200 feedback loop: At the crossroads of signal transduction
in cancer. Int J Cancer. 132:745–754. 2013. View Article : Google Scholar
|
|
27
|
Ueno M, Morizane C, Ikeda M, Okusaka T,
Ishii H and Furuse J: A review of changes to and clinical
implications of the eighth TNM classification of hepatobiliary and
pancreatic cancers. Jpn J Clin Oncol. 49:1073–1082. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y,
Wei G and Chen Y: FBXW7 suppresses epithelial-mesenchymal
transition, stemness and metastatic potential of cholangiocarcinoma
cells. Oncotarget. 6:6310–6325. 2015.PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expres-sion data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Vaquero J, Guedj N, Claperon A, Nguyen
Ho-Bouldoires TH, Paradis V and Fouassier L: Epithelial-mesenchymal
transition in cholangiocarcinoma: From clinical evidence to
regulatory networks. J Hepatol. 66:424–441. 2017. View Article : Google Scholar
|
|
31
|
Bartonicek N, Maag JL and Dinger ME: Long
noncoding RNAs in cancer: Mechanisms of action and technological
advancements. Mol Cancer. 15:432016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Li Z, Leng K, Xu Y, Ji D, Huang L,
Cui Y and Jiang X: ZEB1-AS1: A crucial cancer-related long
non-coding RNA. Cell Prolif. 51:e124232018. View Article : Google Scholar
|
|
33
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qian W, Cai X, Qian Q, Peng W, Yu J, Zhang
X, Tian L and Wang C: LncRNA ZEB1-AS1 promotes pulmonary fibrosis
through ZEB1-mediated epithelial-mesenchymal transition by
competitively binding miR-141-3p. Cell Death Dis. 10:1292019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qu R, Chen X and Zhang C: LncRNA
ZEB1-AS1/miR-409-3p/ZEB1 feedback loop is involved in the
progression of non-small cell lung cancer. Biochem Biophys Res
Commun. 507:450–456. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen C, Feng Y and Wang X: LncRNA ZEB1-AS1
expression in cancer prognosis: Review and meta-analysis. Clin Chim
Acta. 484:265–271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low-dose paclitaxel inhibits the induction of
epidermal-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lu Z, Wang J, Zheng T, Liang Y, Yin D,
Song R, Pei T, Pan S, Jiang H and Liu L: FTY720 inhibits
proliferation and epithelial-mesenchymal transition in
cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer.
14:7832014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Senfter D, Madlener S, Krupitza G and
Mader RM: The microRNA-200 family: Still much to discover. Biomol
Concepts. 7:311–319. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cano A and Nieto MA: Non-coding RNAs take
centre stage in epithelial-to-mesenchymal transition. Trends Cell
Biol. 18:357–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gregory PA, Bracken CP, Bert AG and
Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal
transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Peng F, Jiang J, Yu Y, Tian R, Guo X, Li
X, Shen M, Xu M, Zhu F, Shi C, et al: Direct targeting of
SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma
tumourigenesis and metastasis. Br J Cancer. 109:3092–3104. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Goeppert B, Ernst C, Baer C, Roessler S,
Renner M, Mehrabi A, Hafezi M, Pathil A, Warth A, Stenzinger A, et
al: Cadherin-6 is a putative tumor suppressor and target of
epigenetically dysregulated miR-429 in cholangiocarcinoma.
Epigenetics. 11:780–790. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen C, Yang D, Wang Q and Wang X:
Expression and clinical pathological significance of miR-200a in
concurrent cholangio-carcinoma associated with hepatolithiasis. Med
Sci Monit. 21:3585–3590. 2015. View Article : Google Scholar : PubMed/NCBI
|
